Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Comparison of Electronic Versus Manual Mass-Casualty Incident Triage.

Bolduc C, Maghraby N, Fok P, Luong TM, Homier V.

Prehosp Disaster Med. 2018 Jun;33(3):273-278. doi: 10.1017/S1049023X1800033X. Epub 2018 Apr 17.

PMID:
29661267
2.

Phenolic Compounds and Antioxidant Activity of Phalaenopsis Orchid Hybrids.

Minh TN, Khang do T, Tuyen PT, Minh LT, Anh LH, Quan NV, Ha PT, Quan NT, Toan NP, Elzaawely AA, Xuan TD.

Antioxidants (Basel). 2016 Sep 14;5(3). pii: E31. doi: 10.3390/antiox5030031.

3.

NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells.

Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P.

Cancer Res. 2012 Aug 1;72(15):3735-43. doi: 10.1158/0008-5472.CAN-11-4136. Epub 2012 May 16.

4.

Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.

Mehta DR, Foon KA, Redner RL, Raptis A, Agha M, Hou JZ, Duggal S, Luong TM, Schlesselman JJ, Boyiadzis M.

Leuk Res. 2011 Jul;35(7):885-8. doi: 10.1016/j.leukres.2010.12.030. Epub 2011 Feb 18.

PMID:
21315448
5.

Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia.

McHayleh W, Foon K, Redner R, Sehgal R, Raptis A, Agha M, Luong TM, Schlesselman JJ, Boyiadzis M.

Cancer. 2010 Jun 15;116(12):3001-5. doi: 10.1002/cncr.25078.

7.

Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.

McHayleh W, Sehgal R, Redner RL, Raptis A, Agha M, Natale J, Luong TM, Schlesselman JJ, Foon KA, Boyiadzis M.

Leuk Lymphoma. 2009 Nov;50(11):1848-53. doi: 10.3109/10428190903216788.

PMID:
19860628
8.

A new generalization of Weibull distribution with application to a breast cancer data set.

Wahed AS, Luong TM, Jeong JH.

Stat Med. 2009 Jul 20;28(16):2077-94. doi: 10.1002/sim.3598.

9.

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.

Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM.

Clin Cancer Res. 2008 Nov 1;14(21):7088-94. doi: 10.1158/1078-0432.CCR-08-0529.

10.

Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.

Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, Dacic S, Luong TM, Kim KJ, Dulak AM, Siegfried JM.

Mol Cancer Ther. 2008 Jul;7(7):1913-22. doi: 10.1158/1535-7163.MCT-07-2169.

11.

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.

Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE.

Breast Cancer Res. 2008;10(3):R45. doi: 10.1186/bcr2096. Epub 2008 May 12.

12.

Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.

Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB.

Eur Heart J. 2005 Oct;26(19):1964-70. Epub 2005 May 4.

PMID:
15872036

Supplemental Content

Loading ...
Support Center